Exposure-response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy.

"COMPETING INTERESTS R.deW. serves as an advisor for Merck, Sanofi‐Genzyme, Astellas, Eli Lilly and Company, Bayer and Janssen; reports speaker fees from Sanofi and Merck; grants (institutional) from Bayer and Sanofi; and travel support from Bayer. T.P. reports grants (institutional) from AstraZeneca, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche; honoraria from AstraZeneca, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche; and received travel/accommodation/expenses from Roche, Pfizer, MSD, AstraZeneca, Ipsen. D.C. reports consulting or advisory roles with Janssen Oncology, Roche/Genentech, Astellas Pharma, AstraZeneca, Pfizer, Novartis, Ispen, Bristol‐Myers Squibb, MSD Oncology, Bayer, Eli Lilly and Company, Sanofi, Pierre Fabre, Boehringer Ingelheim; research funding from Janssen Oncology; and travel/accommodation expenses Pfizer, Roche, Bristol‐Myers Squibb and AstraZeneca Spain. A.N. reports employment and stock ownership with Bayer; grants (institutional) from Merck, Astra Zeneca; honoraria from Roche, Merck, Astra Zeneca, Janssen, Foundation Medicine; consultant or adviser role for Merck, Roche, Bayer, Astra Zeneca, Clovis Oncology, Janssen, Incyte, Seattle Genetics/Astellas, Bristol‐Myers Squibb, Rainier Therapeutics; and received travel/accommodation/expenses from Roche, Merck, Astra Zeneca, Janssen. J.‐L.L. reports grants, personal fees and other from Pfizer Korea, Ipsen Korea, BMS, MSD; personal fees from Novartis Korea; personal fees and other from Sanofi Aventis, Astellas Korea; other from Myovant Science, Johnson and Johnson and Amgen; grants and other from Merck, Esai, Amgen; grants and personal fees from AstraZeneca; and grants from Exelixis, Roche, SeaGen. M.S.vdH. reports grants (institutional) from BMS, Roche, AstraZeneca and 4SC; and honoraria (paid to institute) for participation in advisory boards from BMS, Roche, Seagen, AstraZeneca, Janssen, Pfizer and MSD. N.M. reports consulting fees from Janssen, Amgen, Astellas Pharma; honoraria from Janssen, Sanofi, Chugai Pharmaceutical Co.; and has participated on a data safety monitoring board or advisory board for Janssen, Amgen, Chugai Pharmaceutical Co., MSD. A.B. reports consulting fees from ISPEN, BMS and MSD; and honoraria from ISPEN, BMS and MSD. A.F. reports personal fees Pfizer‐Merck, Roche, Seagen, MSD, Ipsen, AAA, Sanofi, Astellas, Astra Zeneca BMS, Janssen, Sanofi Aventis and Amgen. C.N.S. reports Pfizer, MSD, Merck KGaA, AstraZeneca, Astellas, Sanofi‐Genzyme, Roche‐Genentech, Janssen, Bristol‐Myers Squibb, Amgen, Bayer, Foundation Medicine, Immunomedics now Gilead, UroToday, Medscape, NCI; and advisory board role to Seattle Genetics/Astellas. A.D. reports participation in advisory boards for Roche/Genentech, Merck, Exelixis, Seattle Genetics, Jansen, Infinity, and Astra Zeneca. E.Y.Y. reports personal consulting fees from Abbvie, Advanced Accelerator Applications, Bayer, Clovis, Exelixis, Janssen, Merck, Sanofi, Seagen; and research funding to institution (University of Washington) from Bayer, Blue Earth, Daiichi‐Sankyo, Dendreon, Lantheus, Merck, Seagen, Taiho. A.H.Z., A.L. and R.A.W. are employees and shareholders of Eli Lilly and Company. L.G. was an employee of Eli Lilly and Company and was previously a shareholder of Eli Lilly and Company. K.M.B.‐McG. is a former employee of Eli Lilly and Company and is a current shareholder of Eli Lilly and Company. D.P.P. reports consultant fees from Ada Cap (Advanced Accelerator Applications) Amgen, Astellas, AstraZeneca, Bayer, Bicycle Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Clovis Oncology, Eli Lilly and Company, Exelixis, Incyte, Ipsen, Janssen, Mirati, Monopteros, Pfizer, Pharmacyclics, Regeneron, Roche, Seattle Genetics, Urogen; grant support from Ada Cap (Advanced Accelerator Applications), Agensys Inc, Astellas, AstraZeneca, Bayer, BioXcel Therapeutics, Bristol Myers Squibb, Clovis Oncology, Eisai, Eli Lilly and Company, Endocyte, Genentech, Innocrin, MedImmune, Medivation, Merck, Mirati, Novartis, Pfizer, Progenics, Replimune, Roche, Sanofi Aventis, Seattle Genetics; and previous ownership interest/investment in Bellicum and Tyme."

"Funding information Eli Lilly and Company"